Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 680

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 680
---
 3,868,635 |
| Shares issued in connection with the Concurrent Investment            |     |                         |  4,952,579 |
| Shares issued for TuHURA Warrant                                      
 Exercises(1)                                                          |     |                         |  1,395,871 |
| Shares underlying Penny Warrants                                      
 issued(2)                                                             |     |                         |    297,029 |
| Pro Forma weighted average shares outstanding                         |     |                         | 52,798,639 |

| (1) | The aggregate amount of shares issued in connection with TuHURA Warrants exercised following the closing of                                                                                                                            
 the Kintara Merger, consisting of 39,234 exercises which occurred prior to December 31, 2024, with the underlying shares issued already reflected in the TuHURA historical financial statements as of December 31, 2024, and 1,356,637 
 additional exercises that have occurred subsequent to December 31, 2024                                                                                                                                                                |

| (2) | Penny Warrants assumed to be exercised and converted into shares of TuHURA Common Stock as soon as they were 
 exercisable based on the nominal exercise price of $0.01 per share                                           |

Net loss per share to give pro forma effect of both the Kintara Merger as well as the Mergers was calculated using the weighted average shares outstanding as calculated following the consummation of the Kintara Merger, and the issuance of additional shares in connection with the Mergers, assuming the shares were outstanding since January 1, 2024. As the Transactions are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Transactions have been outstanding for the entirety of all periods presented. 454

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The unaudited pro forma condensed combined financial information has been prepared to present the Kineta Merger for the year ended December 31, 2024:

| Numerator:                                                                           |     | For the Year Ended    
 December 31, 2024 (1) |             |   |
|:-------------------------------------------------------------------------------------|:----|:----------------------|------------:|:--|
| Pro Forma Net loss attributable to common stockholders                               |     | $                     | (58,553,596 | ) |
| Den